NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free VYGR Stock Alerts $7.72 +0.15 (+1.98%) (As of 10:58 AM ET) Add Compare Share Share Today's Range$7.57▼$7.7850-Day Range$7.15▼$10.5452-Week Range$6.06▼$14.34Volume68,866 shsAverage Volume912,907 shsMarket Capitalization$419.20 millionP/E Ratio2.50Dividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside155.4% Upside$19.33 Price TargetShort InterestBearish6.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.22Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.64) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.01 out of 5 starsMedical Sector172nd out of 910 stocksBiological Products, Except Diagnostic Industry19th out of 153 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 44.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.3 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 12 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat Follows75 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 34% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 2.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 2.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 163.13.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesApril 23, 2024 | barrons.comNASA's Voyager 1 Phones Home After MonthsApril 23, 2024 | msn.comVoyager 1 sending data to Earth for 1st time in 5 monthsApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 22, 2024 | yahoo.comNASA's Voyager 1 Is Finally Making Sense After Months of Transmitting GibberishApril 22, 2024 | msn.comNASA's Voyager 1 resumes sending engineering updates to EarthApril 22, 2024 | globenewswire.comVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingApril 18, 2024 | reuters.comLouis Vuitton holds 'Voyager' fashion show in ShanghaiApril 18, 2024 | yahoo.comNicolas Ghesquière’s First Voyager Show Was All About Chinese YouthApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 17, 2024 | msn.comNASA tries to jog Voyager 1's memory from 15 billion miles awayApril 17, 2024 | markets.businessinsider.comOptimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic PartnershipsApril 16, 2024 | globenewswire.comVoyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentApril 14, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Shares Down 1.6% April 12, 2024 | msn.comDS9 Predicted Star Trek: Voyager’s Hologram Doctor Fighting For His RightsApril 10, 2024 | msn.comNASA Decodes the Reason Behind Voyager 1's Garbled TransmissionsApril 9, 2024 | msn.comClarity Restored: NASA Pinpoints the Cause of Voyager 1’s Strange Data SignalsApril 9, 2024 | finance.yahoo.comVoyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?April 9, 2024 | msn.comNASA Has Finally Identified The Reason Behind Voyager 1's GibberishApril 8, 2024 | msn.comRecount Voyager 1's interstellar odyssey that outlived NASA expectationsApril 8, 2024 | lse.co.ukVoyager Life cancels merger with Northern Leaf as funding efforts failApril 6, 2024 | forbes.comNASA Discovers Source Of Voyager 1 Glitch In Interstellar SpaceApril 5, 2024 | msn.comNASA engineers discover why Voyager 1 is sending a stream of gibberish from outside our solar systemApril 5, 2024 | msn.comNASA Figured Out Why Its Voyager 1 Probe Has Been Glitching for MonthsApril 5, 2024 | msn.comVoyager’s Epochal Journey: A Billion-Year Odyssey Steered by Alan Cummings’ DedicationApril 5, 2024 | investing.comVoyager Therapeutics COO sells shares worth over $13,000April 3, 2024 | msn.comNASA’s Ingenious Efforts to Restore Voyager 1’s Interstellar Communications on May，2022March 31, 2024 | msn.comRoddenberry’s Vision Reaffirmed Was Important To Star Trek: Voyager ShowrunnerSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/22/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+155.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.09 Trailing P/E Ratio2.45 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins52.93% Pretax Margin53.49% Return on Equity63.89% Return on Assets40.79% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual Sales$250.01 million Price / Sales1.64 Cash Flow$3.05 per share Price / Cash Flow2.48 Book Value$5.37 per share Price / Book1.41Miscellaneous Outstanding Shares54,300,000Free Float51,749,000Market Cap$411.05 million OptionableOptionable Beta0.96 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $825.41kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Jacquelyn Fahey Sandell Esq.J.D., Chief Legal OfficerMs. Michelle Quinn SmithChief Human Resources OfficerMr. G. Andre Turenne (Age 50)Advisor Comp: $600.3kDr. Maria Lopez-Bresnahan M.B.A.M.D., Senior Vice President of Translational Medicine & Clinical DevelopmentMore ExecutivesKey CompetitorsReplimune GroupNASDAQ:REPLTourmaline BioNASDAQ:TRMLOcugenNASDAQ:OCGNLexeo TherapeuticsNASDAQ:LXEOAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 2,030 shares on 4/18/2024Ownership: 0.183%ADAR1 Capital Management LLCBought 185,894 shares on 2/14/2024Ownership: 0.423%Armistice Capital LLCBought 58,000 shares on 2/13/2024Ownership: 9.629%Tower Research Capital LLC TRC Bought 4,809 shares on 2/13/2024Ownership: 0.015%Massachusetts Financial Services Co. MASold 3,505 shares on 2/8/2024Ownership: 0.252%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 7 Wall Street analysts have issued twelve-month price targets for Voyager Therapeutics' stock. Their VYGR share price targets range from $14.00 to $30.00. On average, they anticipate the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 155.4% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 at the beginning of the year. Since then, VYGR shares have decreased by 10.3% and is now trading at $7.57. View the best growth stocks for 2024 here. Are investors shorting Voyager Therapeutics? Voyager Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,330,000 shares, an increase of 44.2% from the March 15th total of 2,310,000 shares. Based on an average daily trading volume, of 750,600 shares, the days-to-cover ratio is currently 4.4 days. View Voyager Therapeutics' Short Interest. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its earnings results on Wednesday, February, 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. The business had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%. What ETFs hold Voyager Therapeutics' stock? ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include Franklin Genomic Advancements ETF (HELX) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
